Corcept (CORT) Director David Mahoney Sells 20,000 Shares

What Happened
David L. Mahoney, a director of Corcept Therapeutics, reported an open-market sale of 20,000 common shares on June 17, 2026. The weighted average sale price was $84.53, for total proceeds of $1,690,506. The filing indicates the sale was a disposition (code S).

Key Details

• Transaction date: 2026-06-17 (reported on Form 4 filed 2026-06-18) — filing appears timely.
• Transaction type: Open-market sale (S).
• Shares sold: 20,000; weighted average price: $84.53; total proceeds: $1,690,506.
• Price range: individual sale prices ranged from $84.44 to $85.11 (see footnote F1). Exact allocation by price not provided; issuer can supply details on request.
• Shares owned after transaction: Not specified in this filing.
• Remarks: Power of attorney under which the form was signed is on file with the SEC.

Context
This was a straightforward open-market sale by a company director. Sales can reflect many non-investment reasons (diversification, personal needs, pre-set plans); they are not by themselves a clear bearish signal. There is no indication in the filing of an option exercise, 10b5‑1 plan, gift, or late filing.